Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia

Am J Hematol. 2013 Mar;88(3):240-1. doi: 10.1002/ajh.23224. Epub 2012 May 6.

Authors

Hossein Sadrzadeh¹, Robert Hasserjian, Amir T Fathi

Affiliation

¹ Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 22565525
DOI: 10.1002/ajh.23224

No abstract available

Publication types

Case Reports

MeSH terms

Abnormal Karyotype
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Cladribine / administration & dosage
Cyclophosphamide / administration & dosage
Fatal Outcome
Humans
Leukemia, Erythroblastic, Acute / etiology
Leukemia, Erythroblastic, Acute / genetics
Leukemia, Erythroblastic, Acute / pathology*
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Male
Myelodysplastic Syndromes / etiology
Myelodysplastic Syndromes / genetics
Myelodysplastic Syndromes / pathology*
Prednisone / administration & dosage
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives
Vincristine / administration & dosage

Substances

Cladribine
Vincristine
Cyclophosphamide
Vidarabine
fludarabine
Prednisone